| Literature DB >> 26783460 |
Shravani Barkund1, Tejas Shah1, Nikhil Ambatkar1, Maithili Gadgil1, Kalpana Joshi1.
Abstract
Asthma is a chronic inflammatory disorder delineated by a heightened immunological response due to environmental or genetic factors. Single nucleotide polymorphism studies have shown that FOXO3a plays a pivotal role in maintaining immunoregulation. Polymorphism in FOXO3a has been linked to inflammatory diseases such as chronic obstructive pulmonary disease (COPD), Rheumatoid Arthritis, and Crohn's disease suggesting that FOXO3a may be associated with asthma. Airway inflammation in asthma is characterized by activation of T helper type 2 (Th2) T cells and Foxo family members are reported to play critical roles in the suppression of T cell activation. Thus this study was undertaken to investigate an association between single nucleotide polymorphism of the FOXO3a (rs13217795, C>T transition) gene and asthma in Indian population. To our knowledge we are the first ones reporting an association between FOXO3a and asthma.Entities:
Year: 2015 PMID: 26783460 PMCID: PMC4689967 DOI: 10.1155/2015/638515
Source DB: PubMed Journal: Mol Biol Int ISSN: 2090-2182
Demographic and clinical characteristics of asthma patients and healthy controls.
| Category | Total | Male | Female | Mean age | FEV1a | FVCb |
|---|---|---|---|---|---|---|
| (years) | (% predicted) | (% predicted) | ||||
| Asthma group | 114 | 69 | 45 | 41.8 ± 8.7 | 64.9 ± 12.7 | 71.3 ± 2.3 |
| Control group | 142 | 78 | 64 | 42.9 ± 11.5 | 93.6 ± 5.4 | 95.0± 4.3 |
aForced expiratory volume in 1 second, bforced vital capacity.
Technical data for analysis of SNP in the human FOXO3a gene.
| Gene name | SNP | Primers | GC content (%) | Annealing temperature (°C) | Restriction enzyme | PCR product size (bp) |
|---|---|---|---|---|---|---|
| FOXO3a | rs13217795 | Forward: 5′-CTCCTTGGTCAGTTTGGTG-3′ | 52.6% | 62°C |
| 667 bp |
New England Biolabs Inc., USA.
Analysis of RFLP fragments.
| Type | Fragment sizes |
|---|---|
| Homozygous wild type (CC) | 667 bp |
| Heterozygous wild type (CT) | 667 bp, 321 bp, and 275 bp |
| Mutant type (TT) | 321 bp and 275 bp |
Figure 1Gel representing typical restriction fragment length polymorphism patterns obtained by subjecting PCR products to restriction digestion by enzyme, PagI (New England Biolabs Inc., USA). Lane 1 consists of the 100 bp DNA marker (Bangalore Genei, India). Lanes 2 and 3 represent RFLP pattern for homozygous mutant alleles (TT). Lanes 4 and 5 represent RFLP pattern for heterozygous (CT) alleles. Lanes 6 and 7 represent RFLP pattern for homozygous wild type (CC) alleles.
The genotype and allele frequencies for asthmatic patients and control subjects of rs13217795 of FOXO3a gene.
| Frequencies |
| Degrees of freedom | |||
|---|---|---|---|---|---|
| Asthmatic patients | Healthy controls | ||||
| ( | ( | ||||
| Genotype | CC | 11 (9.65%) | 72 (50.70%) | <0.0001 | 2 |
| CT | 44 (38.6%)a | 52 (36.61%)a | |||
| TT | 59 (51.75%)b | 18(12.67%)b | |||
|
| |||||
| Allele | C | 66 (28.95%)c | 196 (69.01%)c | <0.0001 | 1 |
| T | 162 (71.05%)c | 88 (30.99%)c | |||
Chi-square test (χ 2).
Odds ratio from genotypic frequency (keeping CC as baseline):
aCT—5.54; 95% confidence interval = 2.48 to 12.62.
bTT—21.45; 95% confidence interval = 8.78 to 53.84.
From allelic frequency:
codds ratio = 5.47; 95% confidence interval = 3.67 to 8.16.
Distribution of the rs13217795, C>T polymorphism according to gender in the study groups.
| Gender | Males | Females | |||
|---|---|---|---|---|---|
| Asthmatic patients ( | Healthy controls ( | Asthmatic patients ( | Healthy controls ( | ||
| Genotype | CC | 9 (13.04%) | 40 (51.28%) | 2 (4.44%) | 32 (50%) |
| CT | 33 (47.82%)a | 29 (37.17%)a | 11 (24.44%)c | 23 (35.93%)c | |
| TT | 27 (39.13%)b | 9 (11.54%)b | 32 (71.11%)d | 9 (14.06%)d | |
|
| |||||
| Allele | C | 51 (36.95%)e | 109 (69.87%)e | 15 (16.66%)f | 87 (67.96%)f |
| T | 87 (63.04%)e | 47 (30.12%)e | 75 (83.33%)f | 41 (32.03%)f | |
Odds ratio from genotypic frequency:
Males: odds ratio keeping CC as baseline:
aCT—5.057; 95% confidence interval = 2.10 to 12.174.
bTT—13.33; 95% confidence interval = 4.689 to 37.911.
Females: odds ratio keeping CC as baseline:
cCT—7.652; 95% confidence interval = 1.5463 to 37.867.
dTT—56.88; 95% confidence interval = 11.386 to 284.219.
Odds ratio from allelic frequency:
eMales: odds ratio = 3.9562; 95% confidence interval = 2.432 to 6.433.
fFemales: odds ratio = 10.6098; 95% confidence interval = 5.4442 to 20.67.